Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Drug Efficacy Amendments of 1962 | Statement: [Kefauver–Harris Drug Amendments of 1962, alsoKnownAs, Drug Efficacy Amendments of 1962]

Target entity: Drug Efficacy Amendments of 1962
Context triple: [Kefauver–Harris Drug Amendments of 1962, alsoKnownAs, Drug Efficacy Amendments of 1962]

• A. Kefauver–Harris Drug Amendments of 1962 chosen
  The Kefauver–Harris Drug Amendments of 1962 are U.S. federal regulations that strengthened drug safety and efficacy requirements, mandating proof of effectiveness and stricter oversight of pharmaceutical marketing and manufacturing.
• B. Medical Device Amendments of 1976
  The Medical Device Amendments of 1976 are U.S. legislation that established a comprehensive regulatory framework for the safety and effectiveness of medical devices, including classification, premarket approval, and performance standards.
• C. Drug Price Competition and Patent Term Restoration Act of 1984
  The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, is a U.S. law that streamlined the approval of generic drugs while providing patent term extensions to brand-name drug manufacturers to balance innovation and competition.
• D. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• E. Celler-Kefauver Act
  The Celler-Kefauver Act is a 1950 U.S. antitrust law that strengthened merger control by closing loopholes in earlier legislation to better prevent anti-competitive acquisitions.
• F. None of above.
• G. Unsure - the case is ambiguous/there is not enough information to decide.